OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SBRY56

J Sainsbury PLC

Food Retail & DistributionVerified

J Sainsbury maintains a flat capital structure with no dilution risk, as basic and diluted shares outstanding are equal at 2.27 billion shares. The company's liquidity risk remains unassessed due to missing balance-sheet inputs and lack of going-concern language in source documents. Profitability metrics remain undisclosed in the valuation snapshot, preventing direct comparison to industry benchmarks for gross margin, EBITDA margin, and ROIC. Analysts have assigned a mean recommendation of 2.77, indicating a mixed outlook with six "buy" and four "hold" ratings. Geographic and segment revenue concentration data is not available in the current dataset, limiting assessment of exposure to regional economic shifts or underperforming business lines. The company's growth trajectory remains undefined without revenue history or outlook deltas. Risk factors include unassessed liquidity risk and limited visibility into capital structure dynamics. No dilution adjustments were applied to valuation multiples, and no recent filings or transcripts have been processed to identify material events.

30-day price · SBRY(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyJ Sainsbury PLC
TickerSBRY.L
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryFood Retail & Distribution
AI analysis

Business. J Sainsbury PLC operates as a food and drug retailer in the United Kingdom, generating revenue primarily through the sale of groceries, household goods, and pharmacy products.

Classification. J Sainsbury is classified under the Food Retail & Distribution industry within the Consumer Non-Cyclicals economic sector, with a confidence level of 0.92.

J Sainsbury maintains a flat capital structure with no dilution risk, as basic and diluted shares outstanding are equal at 2.27 billion shares. The company's liquidity risk remains unassessed due to missing balance-sheet inputs and lack of going-concern language in source documents. Profitability metrics remain undisclosed in the valuation snapshot, preventing direct comparison to industry benchmarks for gross margin, EBITDA margin, and ROIC. Analysts have assigned a mean recommendation of 2.77, indicating a mixed outlook with six "buy" and four "hold" ratings. Geographic and segment revenue concentration data is not available in the current dataset, limiting assessment of exposure to regional economic shifts or underperforming business lines. The company's growth trajectory remains undefined without revenue history or outlook deltas. Risk factors include unassessed liquidity risk and limited visibility into capital structure dynamics. No dilution adjustments were applied to valuation multiples, and no recent filings or transcripts have been processed to identify material events.
Key takeaways
  • No dilution risk identified in current capital structure
  • Analysts show cautious optimism with six "buy" ratings and no "strong buy" recommendations
  • Liquidity risk assessment incomplete due to missing financial disclosures
  • No recent material events reported in processed documents
  • Limited visibility into profitability metrics relative to industry benchmarks
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyGBP
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$29.89B$1.16B$677.0M$961.0M
FY-3$31.49B$609.0M$207.0M$358.0M
FY-2$32.24B$783.0M$137.0M-$379.0M
FY-1$32.77B$914.0M$253.0M$503.0M
FY0$33.65B$926.0M$393.0M$243.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$26.91B$8.42B$25.0M
FY-3$26.16B$7.25B$405.0M
FY-2$25.16B$6.97B$1.98B
FY-1$24.76B$6.76B$2.22B
FY0$18.94B$6.15B$1.07B
PeriodOCFCapExFCFSBC
FY-4$1.01B-$694.0M$961.0M
FY-3$2.19B-$738.0M$358.0M
FY-2$1.97B-$1.56B-$379.0M
FY-1$2.15B-$825.0M$503.0M
FY0$1.06B-$843.0M$243.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Food & Drug Retailing · cohort 184 companies
MetricSBRYActivity
Op margin3.1% medp25 1.2% · p75 6.8%
Net margin2.0% medp25 0.7% · p75 4.1%
Gross margin26.1% medp25 17.2% · p75 32.0%
CapEx / revenue-2.5% medp25 -4.6% · p75 -1.4%
Debt / equity56.0% medp25 16.8% · p75 121.1%
Observations
IR observations
Mean price target346.82 GBP
Median price target345.00 GBP
High price target395.00 GBP
Low price target290.00 GBP
Mean recommendation2.77 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count6.00
Hold count4.00
Sell count3.00
Strong-sell count0.00
Mean EPS estimate0.24 GBP
Last actual EPS0.22 GBP
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-01 11:04 UTC#8a922482
Market quoteclose GBP 327.20 · shares 2.27B diluted
no public URL
2026-04-30 01:58 UTC#bcb0e2ae
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 08:04 UTCJob: 6132b25a